JP Morgan Chase
SAGE

JP Morgan Chase’s Sage Therapeutics SAGE Stock Holding History

JP Morgan Chase’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,000
Closed -$407K – 7675
2024
Q4 		$407K Buy
+75,000
New +$459K ﹤0.01% 5146
2021
Q3 		– Sell
-23,700
Closed -$1.35M – 6746
2021
Q2 		$1.35M Sell
23,700
-86,400
-78% -$6.11M ﹤0.01% 4093
2021
Q1 		$8.24M Buy
110,100
+65,900
+149% +$5.4M ﹤0.01% 2549
2020
Q4 		$3.82M Buy
44,200
+18,900
+75% +$1.39M ﹤0.01% 3022
2020
Q3 		$1.51M Buy
25,300
+24,300
+2,430% +$1.23M ﹤0.01% 3415
2020
Q2 		$42K Buy
+1,000
New +$36.3K ﹤0.01% 4879
2020
Q1 		– Sell
-115,200
Closed -$8.32M – 5668
2019
Q4 		$8.32M Buy
115,200
+115,000
+57,500% +$14.1M ﹤0.01% 2270
2019
Q3 		$28K Hold
200
– – ﹤0.01% 5335
2019
Q2 		$36K Sell
200
-334,800
-100% -$57.1M ﹤0.01% 5302
2019
Q1 		$53.3M Buy
+335,000
New +$48.5M 0.01% 919
2017
Q4 		– Sell
-20,100
Closed -$1.26M – 5558
2017
Q3 		$1.26M Buy
+20,100
New +$1.58M ﹤0.01% 3399

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's SAGE Position: Q3 2025 in Review

JP Morgan Chase sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 132,912 shares — an estimated $1.21M sold.

JP Morgan Chase first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $165M in Q2 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • JP Morgan Chase reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 132,912 Sage Therapeutics shares in Q3 2025, an estimated $1.21M.
  • JP Morgan Chase first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
  • JP Morgan Chase's Sage Therapeutics position peaked at $165M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.